anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: This study aimed to examine the clinical and microbiological characteristics of female patients with recurrent acute pyelonephritis (APN).
METHODS: A retrospective cohort study was conducted at a tertiary care hospital in South Korea from July 2019 to December 2021. All female patients aged ≥ 19 years who were diagnosed with community-acquired APN on admission were enrolled. The recurrent group included patients with APN who experienced urinary tract infections within the previous year. The clinical characteristics, types of causative organisms, major antibiotic resistance, and molecular characteristics of Escherichia coli strains were compared between the recurrent and non-recurrent groups.
RESULTS: A total of 285 patients with APN were analyzed, including 41 (14.4%) in the recurrent group. Compared to the non-recurrent group, the recurrent group had a higher Charlson Comorbidity Index (1.8 ± 2.1 vs. 1.1 ± 1.5; P = 0.01) and a higher proportion of bladder abnormalities, such as neurogenic bladder (12.2% vs. 2.0%; P = 0.001) and urinary catheterization (12.2% vs. 1.6%; P < 0.001). Escherichia coli was the most common causative organism in both groups. The proportion of Klebsiella pneumoniae (17.1% vs. 4.7%; P = 0.007) and Pseudomonas aeruginosa (5.7% vs. 0.5%; P = 0.014) as a causative organism was higher in the recurrent group. Regarding the microbiological characteristics of Escherichia coli, there were no significant differences in the proportion of antibiotic resistance, phylogenetic groups, resistance genes, and virulence factors between the two groups. Multivariable analysis showed that neurogenic bladder and a history of admission or antibiotic use during 1 year prior to inclusion were significantly associated with recurrent APN.
CONCLUSIONS: The proportion of causative organisms except Escherichia coli was higher in the recurrent group than in the non-recurrent group. Neurogenic bladder and a history of admission or antibiotic use during 1 year prior to inclusion were risk factors for recurrent APN.
Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
The inventors used plant materials for which hair growth effects had been proposed, and tested growth promoting effects on four types of cells which are involved in hair formation. As a result, several promising plant materials for promoting the growth of the cells were found. A combination of extracts from these materials showed remarkable new-hair growth effects in tests on new-hair growth in mice. In human monitor tests as well, significant new-hair growth effects were shown, regardless of age or sex, and without any side effects. These features are not seen in conventional hair care products, and thus the present invention comprising a novel combination of plant extracts has sufficient novelty and inventive step. [Problem] Recently, there has been increasing interest in scalp cosmetics, and various attempts have been made to provide a new-hair growth agent. However, none of the conventional products has reached a satisfactory level. The reason for this is that, the causes of hair loss and the mechanisms of new-hair growth are very complicated, and cannot be dealt with by facile ideas. The main cause of hair recession is aging of the scalp and hair follicles. Thus, there is a demand for the development of a new-hair growth agent that takes rejuvenation of the scalp and hair follicles into consideration. [Solution] "Ayurveda", which is a 5000 year old science of longevity in India, often uses plant formulations, and is thus a treasure trove of physiologically active substances. Several hundreds of plant materials considered to have a hair growth effects were selected from this treasure trove, and the growth effects on four types of cells that constitute the hair follicles and the scalp were examined. As a result, plant materials that promote the growth of each type of cell were found. Combinations of these extracts were subjected to systematic new-hair growth testing, using mice. As a result, a combination of plant materials having a remarkable new-hair growth effect was found. This combination, showed heretofore unseen remarkable new-hair growth effects in human monitor tests involving old and young men and women. [Effect] This combination of plant extracts synergistically activated the types of cells that constitute the hair follicles and the scalp and, regardless of age or sex, showed marked hair loss prevention, hair growth and new-hair growth effects, in a short period of time (3-6 months). Furthermore, natural materials are used, and no side effects whatsoever were observed. From the above, the present invention is a boon for most old and young men and women suffering from thinning hair or hair loss.
A drug insert for insertion into a punctum of a patient is disclosed. A drug insert is configured for disposition within an implant (100), the implant being configured for insertion into a lacrimal canaliculus of a patient for providing sustained release of a therapeutic agent to the eye or surrounding tissues or both. The insert has a drug core (110) comprising a therapeutic agent (160) contained in a matrix (170) and a sheath body (120) comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed proximal end of the drug core that releases therapeutic agent to the eye when the drug insert is disposed within the implant and the implant is inserted into the lacrimal canaliculus of the patient. The other end of the drug core is sealed with a medical-grade adhesive. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.
The invention discloses pearsonothuria graeffei fucosylated chondroitin sulfate with a structural formula represented as the following. The main chain is in a chondroitin sulfate A structure. The structure also contains a branched chain composed of fucoidan sulfate. The branched chain is connected on a beta-D-glycuronic acid of the main chain through a glucosidic bond. The substitution manners of sulfate groups are 75%3,4-O-SO4, 20%2,4-O-SO4, and 5%4-O-SO4. The invention also discloses an extraction method of pearsonothuria graeffei fucosylated chondroitin sulfate. The polysaccharide provided by the invention provides a function of anticoagulation or antithrombosis.
A method for utilizing a magnetically controlled pump implanted into a patient's brain or other organ for treatment of a solid tumoral mass. The pump delivers a plurality of medicating agents, including viral and non-viral vectors for gene therapy, and cell therapy, at a controlled rate, corresponding to the specific needs of the patient. The pump comprises a flexible double walled pouch that is formed from two layers of polymer. The pouch is alternately expanded and contracting by magnetic solenoid. When contracted, the therapeutic agent is pushed out of the pouch through a plurality of needles. When the pouch is expanded, surrounding fluid is drawn into the space between the double walls of the pouch from which it is drawn through a catheter to an analyzer. In cases where a tumor resection is not performed, or does not permit use of the MBP device, a catheter will be implanted in or adjacent to the tumoral region. Fluid drawn from the patient is analyzed. The operation of the apparatus and hence the treatment is remotely controlled based on these measurements and displayed through an external controller.
Participants will take the device home and be required to use it for 20 minutes morning and night every day for at least 4 weeks. The SnooZeal records usage time to allow assessment of compliance.
Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
Moderate hepatic impairment: eight patients of Child-Pugh Grade B (Score 7-9). All patients received Sativex treatment.
PURPOSE: A molxifloxacin aqueous formulation and a method of manufacture thereof are provided to enhance quality, content uniformity and accuracy. CONSTITUTION: A manufacturing method of a molxifloxacin aqueous formulation includes a step of dissolving a molxifloxacin free base into base aqueous solution, acid aqueous solution or a mixed solution thereof. The base solution is NaCl aqueous solution. The NaCl aqueous solution is 0.4-1.2% NaCl aqueous solution. 0.05-0.5g of the molxifloxacin glass base is included based on 100ml of the NaCl aqueous solution. The molxifloxacin free base is manufactured by the following steps: melting molxifloxacin acid salt in water extracting the molxifloxacin free base using organic solvent which does not mix with water; and re-crystallizing the molxifloxacin free base by putting an organic solvent which mixes with water.
Patients in the treatment arm will receive DBS of bilateral centromedian nucleus (2 electrodes per patient). DBS is a standard of care treatment option for drug-resistant epilepsy patients who have previously failed VNS at 12 months or more after instigation and optimization of therapy.
Daily measurement of the Body Composition using electrical Bioimpedance Analysis in a scale (seca mBCA 515). Including total body water and weight.
Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.
200 BD and 200 Non-BD patients were checked for psychological symptoms by Symptom Check List 90 Revised (SCL90-R). BD diagnosis was based on the new International Criteria for Behcet's Disease (ICBD). Non-BD patients were patients mimicking BD. All patients were asked to complete the SCL90-R when they attended the clinic for their routine follow-up. The demographic information and disease manifestations including ocular and neurological involvement were registered. For those with visual impairment, SCL90-R was applied by an interviewer. Frequencies and descriptive analysis were measured in both BD and Non-BD groups. Means and standard deviations (SD) of visual acuity were calculated. Data collected from SCL90-R did not have normal distribution in any dimension. The mean values of raw numbers, global severity index (GSI), the positive symptoms total (PST) and the positive symptom distress index (PSDI), were compared by Mann-Whitney U (M-W U) test.).To detect any bias in results due to data collection method, self reported data and reviewer collected data were compared.
To test using a randomised control trial, whether conservative rehabilitation and protected weight bearing versus early weight bearing and accelerated rehabilitation affects patient outcomes post microfracture surgery of the knee.

Current practice in most units is to protect patients from weight bearing prior to entering a conservative physiotherapy rehabilitation program following microfracture surgery of the knee. At our unit we believe that protecting patients from weight bearing post microfracture surgery makes no difference to their outcome and only leads to a longer rehabilitation time and a delayed return to work and sports. Therefore we want to randomise patients who require microfracture surgery of the knee for cartilage defects into 2 post operative rehabilitation groups. One group will be able to weight bear early and will undergo an accelerated rehabilitation program whilst the other will be protected from weight bearing and will undergo a more conservative rehabilitation program. We will then follow patients up over a year and compare outcome data collected at 6 weeks, 3 months, 6 months and 1 year post operatively to see if there was any difference in outcomes between the 2 groups. As secondary outcomes we will also compare the patients in the two groups to see if there is a difference in time taken to return to work and sporting activities
Ten milliliters of 1% lidocaine paracervical anesthetic will be injected at three cervical locations: 1 mL at the tenaculum site (12 o'clock on a clock face) and 4.5 mL each at the 4 o'clock and 8 o'clock positions. A 3 minute waiting period will be used between the administration of the paracervical nerve block and the insertion of IUS to allow the paracervical block to take effect.
Intravenous pre- and post-surgical injection of 0.4% 13-C-Methacetin solution. Dosage is adapted due to body weight (2 mg/kg). A LiMAx-test of \>150 µg/kg/h would correspond to a general ward indication.
Proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) frequently occur together in patients with diabetic retinopathy In the landmark study Protocol S, about 30% of PDR subjects had DME at baseline and 53% of subjects receiving panretinal photocoagulation (PRP) underwent treatment for DME during the 2-year study interval. Vitreous hemorrhaging is one of the most common indications for pars plana vitrectomy (PPV) in patients with PDR. PDR patients undergoing PPV for the treatment of vitreous hemorrhaging often have coexisting DME, although it is often difficult to identify preoperatively because of the media opacification from the vitreous hemorrhage. Following successful PPV and vitreous hemorrhage resolution, PDR patients may then require prolonged DME treatment with repetitive intravitreal injections and/or focal lasers.

PPV with internal limiting membrane (ILM) peeling has been reported to reduce retinal edema and improve visual acuity in patients with DME. Although numerous studies report favorable outcomes in patients undergoing PPV with ILM peeling for the surgical indication of DME, there are presently not any studies evaluating ILM peeling in PDR patients undergoing PPV for the primary indication of vitreous hemorrhaging. Performing ILM peeling in conjunction with the usual techniques for addressing a vitreous hemorrhage (i.e. endolaser PRP, endodiathermy, etc.) during PPV may offer the benefits of better postoperative visual acuity and/or fewer postoperative treatments required to manage DME. In this randomized controlled trial, the authors evaluate the merits of ILM peeling in PDR patients undergoing PPV for the primary indication of vitreous hemorrhaging.
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition that contains an antibody capable of binding to Sclerostin as a protein.SOLUTION: A pharmaceutical composition contains an antibody having a light chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 376 and a heavy chain variable domain consisting of an amino acid sequence shown by SEQ ID No. 378. The antibody binds to Sclerostin as SEQ ID No. 1 with a binding affinity (Kd) lower than, or equal to, 1×10M. or bonds to the sucre loss Canis familiaris var. domesticus of SEQ ID NO 1 by binding affinity (Kd) equal to 1×10M. The pharmaceutical composition can be used for treatment or prevention of a pathologic disorder developed through the medium of Sclerostin or associated with a rise in the Sclerostin level.
Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
Remote Ischemic Preconditioning Group (RIPC):This group will have all the tests as for the control group with the additional component will be preconditioning. One hour prior to procedure candidates in this group will have structured intermittent periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles, which needs 40 minutes.
INTRODUCTION: Lung cancer is the most common type of cancer that causes death worldwide. Systemic inflammation has been shown to play a role in cancer etiopathogenesis and can be activated from oncogenic changes in cancer cells. In our study, the prognostic effects of inflammatory parameters calculated from serum were investigated in lung cancer.
METHOD: One hundred fifteen patients with locally advanced and advanced lung cancer who were diagnosed in our chest diseases clinic between 2013 and 2015 were retrospectively analyzed. The relationship between advanced lung cancer inflammation index (ALI index), serum neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) levels at the time of diagnosis were calculated, and their relationship with overall survival (OS), disease-free survival, and the treatment response and their effect on predicting prognosis were investigated.
FINDINGS: When the ALI value was examined in the group with non-small cell lung, the OS was found to be 9.018 months in the group over 18 years of age and it was 3.78 months in the group below. Low ALI index was significantly associated with short survival ( P <.05). When the NLR values were examined in the entire patient group, OS more than 5 was 5.95 months and less than 9.63 months. A high NLR value was significantly associated with short survival ( P <.05). No significant relationships were detected between PLR and OS. When the determined cut-off values were used, no significant correlation was found between NLR, ALI, and PLR levels and progression-free survival ( P >.05).
CONCLUSION: In our study, it was concluded that elevated NLR levels and low ALI values at the time of diagnosis of advanced-stage lung cancer were associated with poor survival, and those values may be useful in predicting survival and prognosis when the cut-off values were used. These parameters can be useful in routine use because they can be easily calculated without additional costs.
NEW MATERIAL:The peptide of formula A-Ser-Pip-Arg (A is Pro-Asn, Asn or Pro; Pip is pipecolic acid), its derivative or their salt. EXAMPLE:The compound of formula I. USE:An antidemential agent useful for the prevention and treatment of Alzheimers disease, etc. It exhibits strong nootropic action and has extremely low toxicity. PREPARATION:The exemplified compound can be produced e.g. by reacting a compound of formula II (Boc is t-butoxycarbonyl; Bzl is benzyl; OBzl is benzyl ester) with a compound of formula Z-Pro-OSn (Z is benzyloxycarbonyl; OSu is N-hydroxysuccinimide ester) in a mixture of hydrochloric acid and ethyl acetate in the presence of triethylamine and demasking the resultant compound of formula III by reducing with Pd-carbon, etc.
This is a 1-site, randomized, parallel group, double-blind, placebo-controlled, flexible-dose study in which solriamfetol 37.5-150 mg/day will be administered for 12 weeks to 64 outpatient adults with BED by DSM-5 criteria. The study will have 3 phases: a 1-2 week Screening phase to evaluate participant eligibility; a 12-week blinded Treatment phase during which participants will receive solriamfetol or matching placebo; and a 1-week Treatment Discontinuation phase. During the Treatment phase, participants will be evaluated weekly for the first 4 weeks and then biweekly for the next 8 weeks. Solriamfetol will be started at 37.5 mg/day. After 1 week, study drug will be increased to 75 mg/day. If a participant continues to have BED symptoms, study drug may be increased to a maximum of 150 mg/d by Treatment week 6; after that, study drug dose will be held constant. Efficacy will be assessed by measuring the weekly frequency of binge-eating episode days with patient take-home diaries. Regular monitoring of vital signs, laboratory tests, electrocardiograms (ECGs), adverse events, and suicidality will assess safety
Chronic pain is associated with alterations in fundamental cellular processes. Here, we investigate whether Beclin 1, a protein essential for initiating the cellular process of autophagy, is involved in pain processing and is targetable for pain relief. We find that monoallelic deletion of Becn1 increases inflammation-induced mechanical hypersensitivity in male mice. However, in females, loss of Becn1 does not affect inflammation-induced mechanical hypersensitivity. In males, intrathecal delivery of a Beclin 1 activator, tat-beclin 1, reverses inflammation- and nerve injury-induced mechanical hypersensitivity and prevents mechanical hypersensitivity induced by brain-derived neurotrophic factor (BDNF), a mediator of inflammatory and neuropathic pain. Pain signaling pathways converge on the enhancement of N-methyl-D-aspartate receptors (NMDARs) in spinal dorsal horn neurons. The loss of Becn1 upregulates synaptic NMDAR-mediated currents in dorsal horn neurons from males but not females. We conclude that inhibition of Beclin 1 in the dorsal horn is critical in mediating inflammatory and neuropathic pain signaling pathways in males.
CHD is a disease that is characterized by narrowing of the coronary arteries that supply blood to the heart. As a result, insufficient amounts of oxygen and nutrients reach the heart, which can cause chest pain or heart attack. Studies have shown that people's socioeconomic status is associated with their health, and that African Americans experience the highest rates of heart disease in the U.S. The Jackson Heart Study (JHS) is currently being conducted in Jackson, Mississippi, and is studying the factors that influence the development of cardiovascular disease in African American men and women. This study will examine data from the JHS to determine the effect of socioeconomic status and psychosocial factors on CHD risk in African Americans in Mississippi.

This study will recruit participants from the JHS only. Participants will report to the study site at least once for 4.5 hours for baseline measurements. Visits will include measurements of body size and blood pressure, an electrocardiogram, an echocardiogram, an ultrasound of the carotid artery, blood and urine collection, a lung function test, and interviews regarding health status and sociocultural aspects of life. Follow-up evaluations will occur 5 and 10 years after starting the study. Outcomes will include self-report and electrocardiogram-defined CHD, as well as measures of various social and psychological factors.
Hypospadias repair is a surgery that is, unfortunately, fraught with a high complication rate with problems that include urethrocutaneous fistula formation, complete wound breakdown, glans dehiscence, urethral diverticulum formation, retraction of the urethral meatus, urethral stricture, and meatal stenosis . Failure of a proximal hypospadias repair (i.e. the development of a post-operative complication) is unpredictable, and few modifiable risk factors having been identified. Complications necessitate subsequent surgical intervention for pediatric patients, which must be carried out under general anesthesia. Evidence regarding the harms of multiple general anesthetics for children is increasing. Additionally, with each surgical revision comes the morbidity associated with another post-surgical convalescence. Thus, any measure that can be gained as a way to increase the rate of success of proximal hypospadias repair would be of help to all pediatric urologists and patients with hypospadias. The proposed intervention of administering a 5 day course of placebo versus oral steroids at a dose equivalent to what is given for outpatient treatment of asthma exacerbations, is expected to have very low risk. This would be the only variation from the current practice and one that has never been studied in the past. Thus, it would be worthwhile to perform use scientific methods to determine if the administration of a short course of oral steroids is of benefit to healing and minimization of post-operative complications for hypospadias patients.